An α-galactosidase inhibitor and chaperone
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

1-Deoxygalactonojirimycin (hydrochloride)

Item No. 17179

Technical Information
Formal Name
(2R,3S,4R,5S)-2-(hydroxymethyl)-3,4,5-piperidinetriol, monohydrochloride
CAS Number
75172-81-5
Synonyms
  • DGJ
  • Migalastat
Molecular Formula
C6H13NO4 • HCl
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMSO: 10 mg/mlPBS (pH 7.2): 1 mg/ml
λmax
314 nm
SMILES
O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)NC1.Cl
InChi Code
InChI=1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3;/h3-11H,1-2H2;1H/t3-,4+,5+,6-;/m1./s1
InChi Key
ZJIHMALTJRDNQI-OLALXQGDSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    1-Deoxygalactonojirimycin is a competititve inhibitor of α-galactosidase (IC50 = 40 nM).1 At subinhibitory concentrations, 1-Deoxygalactonojirimycin binds to α-galactosidase and chaperones unstable enzyme variants through the endoplasmic reticulum, allowing its movement into lysosomes.2,3 Pharmacological chaperones, including 1-Deoxygalactonojirimycin, are used to promote lysosomal delivery of unstable proteins in lysosomal storage disorders, like Fabry disease.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Asano, N., Ishii, S., Kizu, H., et alIn vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur. J. Biochem. 267(13), 4179-4186 (2000).

    2. Ishii, S., Chang, H.H., Yoshioka, H., et alPreclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J. Pharmacol. Exp. Ther. 328(3), 723-731 (2009).

    3. Siekierska, A., De Baets, G., Ruemers, J., et alα-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. The Journal of Biological Chemisty 287(34), 28386-28397 (2012).